**Sulfamide-substituted-BODIPY based fluorescence drugs: Synthesis, spectral characteristics, molecular docking, and bioactivity**

**Feng Zhao1, Yuling Wang2, and Guofan Jin2\***

1Affiliated hospital of Jiangsu University, Zhenjiang 212013, R.P. China

2School of Pharmacy, Jiangsu University, Zhenjiang 212013, R.P. China

E-mail address: organicboron@ujs.edu.cn

**Supporting information**

**Table of Content**

**S-1····································································1H-NMR, 13C-NMR and ITMS of Compound 2**

**S-2····································································1H-NMR, 13C-NMR and ITMS of Compound 3**

**S-3···································································· 1H-NMR, 13C-NMR and ITMS of Compound 4**

Fig S1.tif

Figure S1. 1H NMR of compound **2**.

Fig S2.tif

Figure S2. 13C NMR of compound **2**.

Fig S3.tif

Figure S3. ITMS (ESI+) of compound **2**.

**S-1····································································1H-NMR, 13C-NMR and ITMS of Compound 2**

Fig S4.tif

Figure S4. 1H NMR of compound **3**.

Fig S5.tif

Figure S5. 13C NMR of compound **3**.

Fig S6.tif

Figure S6. ITMS (ESI+) of compound **3**.

**S-2····································································1H-NMR, 13C-NMR and ITMS of Compound 3**

Fig S7.tif

Figure S7. 1H NMR of compound **4**.

Fig S8.tif

Figure S8. 13C NMR of compound **4**.

Fig S9.tif

Figure S9. ITMS (ESI+) of compound **4**.

**S-3····································································1H-NMR, 13C-NMR and ITMS of Compound 4**